Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW685698X in vasomotor rhinitis
NCT00117325Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2005
- Primary completion
- Feb 2006
- Modality
- Orthosteric Ligands
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in vasomotor rhinitis (VMR) comparing GW685698X with Placebo (2 arms). Primary endpoint: Reflective Total Nasal Symptom Score at 4 weeks. Started Jul 2005; status: completed.
02
Drugs
fluticasone
03
Conditions
vasomotor rhinitis (VMR)
Beyond the preview
Go deeper on NCT00117325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00117325.